Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmaceutical MNCs Reap Bigger China Market Share

This article was originally published in PharmAsia News

Executive Summary

China's pharmaceutical industry constitutes a key sector for overseas investment. In 2006, 1,500 joint ventures and multinational companies made up 30 percent of drug manufacturers in the country. Foreign corporations accounted for 27 percent of China's medical revenue, capturing up to 65 percent and 80 percent of the market for drugs and medical devices, respectively. China Chamber of Commerce of Medicines & Health Products Importers & Exporters (CCCMHPIE) says in a report that local companies are losing market share rapidly due to lagging technology, unfair domestic pricing policies, distribution and other problems. Industry players call for the establishment of a cooperation platform for relevant business communities to prevent the further erosion of the local market. (Click here for more)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel